<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077142</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-007</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-01007</secondary_id>
    <secondary_id>TAIHO-TAC101</secondary_id>
    <secondary_id>NCI-1528</secondary_id>
    <secondary_id>CDR0000349508</secondary_id>
    <nct_id>NCT00077142</nct_id>
  </id_info>
  <brief_title>TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)</brief_title>
  <official_title>Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to&#xD;
      see how well it works in treating patients with advanced hepatocellular carcinoma (liver&#xD;
      cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Phase I&#xD;
&#xD;
        -  Primary&#xD;
&#xD;
             -  Determine the maximum tolerated dose (MTD) of TAC-101 in patients with advanced&#xD;
                hepatocellular carcinoma.&#xD;
&#xD;
             -  Determine the safety of 2 consecutive courses of this drug in these patients.&#xD;
&#xD;
             -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
             -  Determine the toxic and adverse effects profile of this drug in these patients.&#xD;
&#xD;
      Phase II&#xD;
&#xD;
        -  Primary&#xD;
&#xD;
             -  Determine the objective antitumor response rate in patients treated with this drug&#xD;
                at the MTD.&#xD;
&#xD;
        -  Secondary&#xD;
&#xD;
             -  Determine the overall survival time of patients treated with this drug.&#xD;
&#xD;
             -  Determine the time to disease progression in patients treated with this drug.&#xD;
&#xD;
             -  Determine the duration of observed objective response, using WHO criteria and&#xD;
                measurements of serum alpha-fetoprotein concentrations, in patients treated with&#xD;
                this drug.&#xD;
&#xD;
             -  Determine the time to treatment failure in patients treated with this drug.&#xD;
&#xD;
             -  Determine the safety and tolerability of intermittent treatment with this drug in&#xD;
                these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
        -  Phase I: Patients receive oral TAC-101 once daily on days 1-14. Treatment repeats every&#xD;
           21 days for 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of TAC-101 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive oral TAC-101 at the MTD (determined in phase I) once daily on&#xD;
           days 1-14. Courses repeat every 21 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 35-60 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-18 patients for the phase I portion and 21-41 patients for&#xD;
      the phase II portion will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of TAC-101</measure>
    <time_frame>60 Days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>TAC-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAC-101</intervention_name>
    <description>Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.</description>
    <arm_group_label>TAC-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hepatocellular carcinoma&#xD;
&#xD;
          -  At least 1 previously unirradiated, bidimensionally measurable lesion greater than 20&#xD;
             mm by MRI or conventional CT scan OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  Patients with CNS involvement must have completed appropriate treatment and have no&#xD;
             progressive neurologic deficits within the past 28 days&#xD;
&#xD;
          -  No carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  WBC ≥ 2,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 40,000/mm^3&#xD;
&#xD;
          -  No abnormal bleeding or clotting&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No grade C Child-Pugh cirrhosis&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Albumin ≥ 2.8 g/dL&#xD;
&#xD;
          -  INR ≤ 1.5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior deep vein thrombosis&#xD;
&#xD;
          -  No prior superficial venous thrombosis&#xD;
&#xD;
          -  No family history of thromboembolism in a first-degree relative&#xD;
&#xD;
          -  No lower extremity thromboses by Doppler ultrasound (unless a subsequent venous&#xD;
             angiography confirms a false positive ultrasound)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No prior pulmonary embolism&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception, except oral contraceptives&#xD;
             containing estrogen&#xD;
&#xD;
          -  Fasting triglycerides ≤ 400 mg/dL for men or ≤ 325 mg/dL for women&#xD;
&#xD;
          -  No other malignancy within the past 3 years except inactive nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled metabolic disorders, other nonmalignant organ or systemic disease, or&#xD;
             secondary effects of cancer that induce a high medical risk&#xD;
&#xD;
          -  No known allergy or hypersensitivity to TAC-101 or its components&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior thalidomide&#xD;
&#xD;
          -  No prior putative antiangiogenesis therapy&#xD;
&#xD;
          -  Prior interferon allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent estrogen products&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 21 days since prior radiotherapy, except small portal radiotherapy used for&#xD;
             the palliation of isolated, symptomatic, osseous metastases&#xD;
&#xD;
          -  No prior radiotherapy to evaluable lesions&#xD;
&#xD;
          -  No concurrent radiotherapy unless for bone pain that is present before beginning study&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior anticancer treatment allowed provided there is clear evidence of progressive&#xD;
             disease after the most recent treatment&#xD;
&#xD;
          -  More than 21 days since prior anticancer therapy and recovered&#xD;
&#xD;
          -  No more than 2 prior treatment regimens&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulants&#xD;
&#xD;
               -  Concurrent low-dose warfarin for prophylactic care of indwelling venous access&#xD;
                  devices allowed&#xD;
&#xD;
          -  No concurrent azoles or tetracyclines&#xD;
&#xD;
          -  No concurrent medications known or suspected to increase risk of venous&#xD;
             thromboembolism&#xD;
&#xD;
          -  No other concurrent retinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie B. Thomas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <results_reference>
    <citation>Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27.</citation>
    <PMID>18504614</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2004</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>Oral TAC-101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

